Amlodipine/candesartan cilexetil - CJ HealthCare

Drug Profile

Amlodipine/candesartan cilexetil - CJ HealthCare

Alternative Names: Amlodipine besylate/candesartan cilexetil; CJ 30059; Machkhan

Latest Information Update: 05 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CJ HealthCare
  • Class Antihypertensives; Benzimidazoles; Biphenyl compounds; Dihydropyridines; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Essential hypertension
  • No development reported Angina pectoris

Most Recent Events

  • 05 Sep 2017 No development reported - Phase-I for Angina pectoris (In volunteers) in South Korea (PO)
  • 31 Dec 2016 Launched for Essential hypertension in South Korea (PO) (CJ HealthCare website, September 2017)
  • 24 Jun 2016 Registered for Essential hypertension in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top